Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2024-01-04 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2024-01-04 English
PRIMARY DOCUMENT
Director's Dealing
2023-12-06 English
PRIMARY DOCUMENT
Director's Dealing
2023-12-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or material definitive agreements by a company. The text describes an amendment to a development funding and royalties agreement between Ligand Pharmaceuticals and Palvella Therapeutics, including financial terms and strategic partnership details. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. It is not an earnings release, proxy statement, or management discussion. The document is a regulatory filing announcing a material contract event, consistent with the purpose of Form 8-K filings. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7998 characters) and content support this classification with high confidence.
2023-12-01 English
8-K/A
Earnings Release Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, which is an amendment to a previously filed Form 8-K. It specifically amends the company's earnings release issued on November 8, 2023, correcting financial figures related to the quarter ended September 30, 2023. The document includes detailed financial adjustments and references the original earnings release and the Form 10-Q for the same period. The presence of detailed financial results and corrections to an earnings release indicates this is an amendment to an Earnings Release rather than a full quarterly or annual report. The document is about the amended earnings release, which is a detailed announcement of quarterly financial results. Therefore, the appropriate classification is Earnings Release (ER). The document length (5337 characters) supports that it contains substantive content rather than just a brief announcement or certification. Confidence is high due to the clear identification of the document as an amended earnings release with financial details.
2023-11-10 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.